EUELC project: a multi-centre, multipurpose study to investigate early stage NSCLC, and to establish a biobank for ongoing collaboration

The European Early Lung Cancer (EUELC) project aims to determine if specific genetic alterations occurring in lung carcinogenesis are detectable in the respiratory epithelium. In order to pursue this objective, nonsmall cell lung cancer (NSCLC) patients with a very high risk of developing progressive lung cancer were recruited from 12 centres in eight European countries: France, Germany, southern Ireland, Italy, the Netherlands, Poland, Spain and the UK. In addition, NSCLC patients were followed up every 6 months for 36 months. A European Bronchial Tissue Bank was set up at the University of Liverpool (Liverpool, UK) to optimise the use of biological specimens. The molecular–pathological investigations were subdivided into specific work packages that were delivered by EUELC Partners. The work packages encompassed mutational analysis, genetic instability, methylation profiling, expression profiling utilising immunohistochemistry and chip-based technologies, as well as in-depth analysis of FHIT and RARβ genes, the telomerase catalytic subunit hTERT and genotyping of susceptibility genes in specific pathways. The EUELC project engendered a tremendous collaborative effort, and it enabled the EUELC Partners to establish protocols for assessing molecular biomarkers in early lung cancer with the view to using such biomarkers for early diagnosis and as intermediate end-points in future chemopreventive programmes.

[1]  Xifeng Wu,et al.  Cancer diagnosis in first-degree relatives and non-small cell lung cancer risk: results from a multi-centre case-control study in Europe. , 2009, European journal of cancer.

[2]  E. Brambilla,et al.  Fragile histidine triad gene inactivation in lung cancer: the European Early Lung Cancer project. , 2009, American journal of respiratory and critical care medicine.

[3]  Simon Heath,et al.  Lung cancer susceptibility locus at 5p15.33 , 2008, Nature Genetics.

[4]  Christopher I Amos,et al.  Common 5p15.33 and 6p21.33 variants influence lung cancer risk , 2008, Nature Genetics.

[5]  S. Duffy,et al.  A global approach to cancer-screening trials. , 2008, The Lancet. Oncology.

[6]  S. Lippman,et al.  Lung cancer. , 2008, The New England journal of medicine.

[7]  G. Mills,et al.  Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1 , 2008, Nature Genetics.

[8]  Daniel F. Gudbjartsson,et al.  A variant associated with nicotine dependence, lung cancer and peripheral arterial disease , 2008, Nature.

[9]  Paolo Vineis,et al.  A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 , 2008, Nature.

[10]  S. Duffy,et al.  The LLP risk model: an individual risk prediction model for lung cancer , 2007, British Journal of Cancer.

[11]  S. Rogers,et al.  Quantitative methylation analysis of resection margins and lymph nodes in oral squamous cell carcinoma. , 2007, The British journal of oral & maxillofacial surgery.

[12]  Haesook T. Kim Cumulative Incidence in Competing Risks Data and Competing Risks Regression Analysis , 2007, Clinical Cancer Research.

[13]  Gorka Bastarrika,et al.  Molecular Profiling of Computed Tomography Screen-Detected Lung Nodules Shows Multiple Malignant Features , 2006, Cancer Epidemiology Biomarkers & Prevention.

[14]  Pierre P Massion,et al.  Novel strategies for the early detection and prevention of lung cancer. , 2005, Seminars in oncology.

[15]  J. Ferlay,et al.  Global Cancer Statistics, 2002 , 2005, CA: a cancer journal for clinicians.

[16]  Dimitrios Iliopoulos,et al.  Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer , 2005, Oncogene.

[17]  L. Dwyer-Nield,et al.  Relative amounts of antagonistic splicing factors, hnRNP A1 and ASF/SF2, change during neoplastic lung growth: Implications for pre‐mRNA processing , 2004, Molecular carcinogenesis.

[18]  S. Vicent,et al.  αCP-4, Encoded by a Putative Tumor Suppressor Gene at 3p21, But Not Its Alternative Splice Variant αCP-4a, Is Underexpressed in Lung Cancer , 2004, Cancer Research.

[19]  J. Berkhof,et al.  Elevated hTERT mRNA levels: A potential determinant of bronchial squamous cell carcinoma (in situ) , 2004, International journal of cancer.

[20]  U. Pastorino,et al.  Quantification of free circulating DNA as a diagnostic marker in lung cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  Elisabeth Brambilla,et al.  Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines , 2003, The Journal of pathology.

[22]  Y. Pekarsky,et al.  FHIT as Tumor Suppressor: Mechanisms and Therapeutic Opportunities , 2002, Cancer biology & therapy.

[23]  P. Maloney,et al.  Cancer-specific genomic instability in bronchial lavage: a molecular tool for lung cancer detection. , 2001, Cancer research.

[24]  F. Alla,et al.  Retinoic acid receptor and retinoid X receptor alterations in lung cancer precursor lesions. , 2000, Cancer research.

[25]  W. Prime,et al.  Genetic alterations in bronchial lavage as a potential marker for individuals with a high risk of developing lung cancer. , 1999, Cancer research.

[26]  P. Hainaut,et al.  A specific spectrum of p53 mutations in lung cancer from smokers: review of mutations compiled in the IARC p53 database. , 1998, Environmental health perspectives.

[27]  J. Huisman The Netherlands , 1996, The Lancet.

[28]  C. Croce,et al.  The FHIT Gene at 3p14.2 Is Abnormal in Lung Cancer , 1996, Cell.

[29]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[30]  C. Henschke,et al.  Molecular characterization of small peripheral lung tumors based on the analysis of fine needle aspirates. , 2008, Histology and histopathology.

[31]  S. Vicent,et al.  Alpha CP-4, encoded by a putative tumor suppressor gene at 3p21, but not its alternative splice variant alpha CP-4a, is underexpressed in lung cancer. , 2004, Cancer Research.

[32]  V. Somers,et al.  Detection of K-ras point mutations in sputum from patients with adenocarcinoma of the lung by point-EXACCT. , 2003, Methods in molecular medicine.

[33]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[34]  H. Hansen,et al.  Lung cancer. , 1990, Cancer chemotherapy and biological response modifiers.